Policy & Regulation
AmpliPhi and Australian Organisations to Collaborate on Expanded Access for Bacteriophage Therapeutics
21 March 2018 - - San Diego, California-based developer of therapies for antibiotic-resistant infections using bacteriophage-based technology AmpliPhi Biosciences Corp. (NYSE MKT: APHB) will collaborate with the Western Sydney Local Health District and the Westmead Institute for Medical Research, based in Sydney, Australia, the company said.
The agreement covers compassionate use treatment of patients with severe Staphylococcus aureus and Pseudomonas aeruginosa infections with AmpliPhi's investigational bacteriophage therapeutics AB-SA01 and AB-PA01.
To date, several critically ill patients have received AB-SA01 or AB-PA01 at the Westmead Hospital, under the Australian Therapeutic Goods Administration's Special Access Scheme guidelines.
This new agreement will expand and is expected to accelerate the collaboration to supply AB-SA01 and AB-PA01 for additional patients with serious and life-threatening infections, who do not respond to antibiotics, while collecting clinical and microbiological data.
AmpliPhi Biosciences is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology.
Its lead product candidates target multidrug-resistant S. aureus and P. aeruginosa, which are included on the WHO's 2017 Priority Pathogens List.
Login
Username:

Password: